Soliman Wael, Sander Birgit, Soliman Kamell Abd El-Naser, Yehya Sameer, Rahamn Mohamed Saad Abdel, Larsen Michael
Department of Ophthalmology, Glostrup Hospital, University of Copenhagen, Copenhagen, Denmark.
Acta Ophthalmol. 2008 May;86(3):284-91. doi: 10.1111/j.1600-0420.2007.01048.x. Epub 2007 Nov 13.
To assess the predictive value of optical coherence tomography (OCT) mapping of retinal thickness and intraretinal morphological changes after macular grid for diffuse diabetic macular oedema (DMO).
We carried out a prospective, non-controlled, case series study, in which 28 consecutive eyes with previously untreated diffuse DMO underwent fundus photography and OCT at baseline and at 1, 3 and 6 months after treatment.
Macular photocoagulation was followed by a significant reduction in retinal thickness in the foveal centre (- 80 microm) and in the foveal subfield (- 65 microm) from baseline to 6 months (p < 0.01). The bulk of the reduction in retinal thickness and macular volume was manifest after 1 month. No significant change in retinal thickness occurred from 1 to 3 months or from 1 to 6 months in any macular subfield (p > 0.05). The relative decrease in retinal thickness at 6 months was highest in the foveal centre (- 22%), followed by the foveal region (- 18%), the inner parafoveal region (- 8%), and the outer parafoveal region (- 2%). Thus, the effect of photocoagulation on retinal thickness decreased with increasing eccentricity (p < 0.025). Overall, there was no statistically significant change in best corrected visual acuity (BCVA) between baseline and follow-up (p < 0.05), but changes in foveal subfield thickness and changes in VA were highly correlated (r = 0.66, p < 0.0001). Visual outcome (final BCVA) and final foveal subfield thickness at 6 months were correlated with the pattern of intraretinal morphological changes at baseline (Spearman's correlation coefficient r = - 0.41, p = 0.03 and r = 0.45, p = 0.02, respectively). In addition, visual outcome (final BCVA) and final foveal subfield thickness at 6 months were correlated with baseline foveal thickness (Spearman's correlation coefficient (r = - 0.37, p = 0.05 and r = 0.5, p = 0.01, respectively).
It seems that the 1-month time-point after macular laser treatment is a critical point for establishing the outcome of this modality of management of DMO. Baseline OCT mapping of intraretinal fluid accumulation patterns and foveal thickness can help to predict the final visual outcome and final foveal thickness, but not the absolute change in either of these parameters after macular laser therapy.
评估黄斑格栅光凝治疗弥漫性糖尿病性黄斑水肿(DMO)后,光学相干断层扫描(OCT)测量的视网膜厚度及视网膜内形态学变化的预测价值。
我们开展了一项前瞻性、非对照病例系列研究,28只既往未治疗的弥漫性DMO患眼在基线期以及治疗后1、3和6个月接受了眼底照相和OCT检查。
黄斑光凝治疗后,从基线期到6个月,黄斑中心凹(-80微米)和黄斑中心凹子区域(-65微米)的视网膜厚度显著降低(p<0.01)。视网膜厚度和黄斑体积的大部分降低在1个月后显现。在任何黄斑子区域,从1个月到3个月或从1个月到6个月,视网膜厚度均无显著变化(p>0.05)。6个月时视网膜厚度的相对降低在黄斑中心凹最高(-22%),其次是黄斑区域(-18%)、黄斑内旁中心区域(-8%)和黄斑外旁中心区域(-2%)。因此,光凝对视网膜厚度的影响随偏心度增加而降低(p<0.025)。总体而言,基线期和随访期之间最佳矫正视力(BCVA)无统计学显著变化(p<0.05),但黄斑中心凹子区域厚度变化与视力变化高度相关(r=0.66,p<0.0001)。6个月时的视觉预后(最终BCVA)和最终黄斑中心凹子区域厚度与基线期视网膜内形态学变化模式相关(斯皮尔曼相关系数r分别为-0.41,p=0.03和r=0.45,p=0.02)。此外,6个月时的视觉预后(最终BCVA)和最终黄斑中心凹子区域厚度与基线期黄斑中心凹厚度相关(斯皮尔曼相关系数分别为r=-0.37,p=0.05和r=0.5,p=0.01)。
黄斑激光治疗后1个月似乎是确定DMO这种治疗方式预后的关键点。基线期视网膜内液体积聚模式和黄斑中心凹厚度的OCT测量有助于预测最终视觉预后和最终黄斑中心凹厚度,但无法预测黄斑激光治疗后这些参数的绝对变化。